For research use only. Not for therapeutic Use.
Gatipotuzumab（Cat No.:I042092）is an investigational monoclonal antibody targeting the tumor-associated antigen SLC44A4, which is overexpressed in several cancers, including non-small cell lung cancer (NSCLC) and ovarian cancer. By binding to SLC44A4, gatipotuzumab aims to inhibit cancer cell growth and induce immune system recognition of tumor cells. It is being studied in clinical trials to evaluate its safety, efficacy, and potential as a targeted therapy for cancers that express this antigen. The goal is to assess its ability to improve treatment outcomes, either alone or in combination with other cancer therapies.
| Catalog Number | I042092 |
| CAS Number | 1264737-26-9 |
| Purity | ≥95% |
